InvestSMART

Atomo Diagnostics Limited (ASX:AT1)

ALERT: Price-sensitive ASX Announcement for AT1
Current share price for AT1 : $0.018 0 (0%)+
Announcement
Release
19 Aug 2026 9:55AM
Price at Release
$0.018
Full Release
download
Summary
Atomo Diagnostics Limited announced the transition of its leadership with John Kelly, the co-founder, stepping down as Managing Director and CEO. Dr. Cheri Walker, based in the US, has been appointed as interim CEO to better align with the company's primary commercial markets in the US and Europe. This transition marks a shift in focus from technical development to a more commercial and sales-driven approach, as Atomo continues to scale its presence internationally. Dr. Walker's extensive experience in life sciences positions her well for this role. The company will conduct a global search for a permanent CEO while Mr. Kelly will support the transition.
Key Points
  • John Kelly steps down as Managing Director and CEO effective 19 August 2026.
  • Dr. Cheri Walker appointed as interim CEO with immediate effect.
  • Transition in leadership aligns with growing international markets, particularly in the US and Europe.
  • Dr. Walker brings over 25 years of experience in life sciences and diagnostics.
  • Atomo Diagnostics shifts focus towards commercialization and sales-driven growth.
  • A global search will be conducted to find a permanent CEO.
  • Mr. Kelly will support Dr. Walker during the transition phase.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.